In 2022, multinational pharmaceutical companies will continue to accelerate their "weight reduction" in China

In recent years, multinational giants, led by Roche, Pfizer, AstraZeneca, Novartis, Eli Lilly, Bristol-Myers Squibb, etc.
, are intensively "slimming" and actively seeking change; and from this year's perspective, this trend is becoming more and more Obviously
.
For example, in the near future, many pharmaceutical companies have failed to elect a layoff plan
.
Recently, news has shown that U.
S.
Biopharmaceuticals will adjust the personnel of the Parkinson team
.
The adjusted product line is Yopro (rotigotine
.
It is understood that the reason for the layoffs is that Yopro (rotigotine) has negotiated national medical insurance twice, but they are not eligible for medical insurance
.
In this regard, the company believes that the product The overall output is too low and the business volume is not enough
.
This adjustment plan is implemented .
However, because the product line is only the product of Upro, there are not many domestic sales representatives, so the company plans to transfer internally or lay off a small number of employees.
The compensation plan has not yet been announced
.
According to data, in June 2018, Utimes announced that its innovative drug Yopro (rotigotine patch) was approved by the National Food and Drug Administration for monotherapy (not with levodopa).
Combined use) early idiopathic Parkinson’s disease symptoms and signs, or combined with levodopa for the treatment of various stages in the course of the disease
.
On November 4 of the same year, Utimes announced its innovative drug Upro (rotigotine paste).
The film) was officially launched in China, and the first prescription was issued on October 17, bringing new options to approximately 2.
6 million Parkinson’s disease patients in China
.
In addition, in the sixth batch of centralized procurement recently, seven products have won the bidding, Novo Nordisk, which has dropped by about 40%, also plans to lay off 15-20% of its employees nationwide.
According to insiders, there will be N+1 compensation for the layoffs
.
The specific notice must be formalized.
Announcement shall prevail
.
The analysis believes that the products declared by Novo Nordisk this time are basically stuck in the line and won the bid, so some employees of the dedicated line may be laid
off.
The industry believes that the layoffs of the above-mentioned multinational pharmaceutical companies in China are actually not Nothing new
.
Since the beginning of this year, the wave of layoffs by multinational pharmaceutical companies has continued to emerge, including Sanofi, Amgen, Gilead, Novartis, GlaxoSmithKline, Mylan, Gilead, Johnson & Johnson, AstraZeneca and many other layoffs throughout the year
.
The industry believes that this is mainly due to the impact of a series of domestic medical reform policies
.
Among them, especially in the context of the normalization of centralized procurement, gold sales have been hit hard, and the pharmaceutical sales environment has been reshaped, all forcing multinational pharmaceutical companies to accelerate adjustments to adapt to China's pharmaceutical policy changes
.
In addition to layoffs, in fact, many multinational pharmaceutical companies including Pfizer, Roche, Merck and other companies have adjusted their organizational structures in China since the beginning of this year.
They have implemented business line divestitures and mergers, replacement of senior candidates, and focus on innovative drugs.
Multiple initiatives
.
It is worth mentioning that, from an overall perspective, the main focus of the adjustment of the business structure of multinational pharmaceutical companies is to adjust the two aspects of mature drugs and innovative drugs
.
The analysis believes that in recent years, with the intensified changes in the domestic pharmaceutical market and the greater pressure on the performance of pharmaceutical companies, the transformation of multinational pharmaceutical companies is also imminent, which has led to frequent business adjustments and constant layoffs
.
Judging from the acceleration of personnel and strategic adjustments of multinational pharmaceutical companies, it is expected that this "slimming wave" will continue in 2022
.